Mycenax Biotech Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was TWD 774.27 million compared to TWD 665.34 million a year ago. Net loss was TWD 89.86 million compared to net income of TWD 30.95 million a year ago.

Basic loss per share from continuing operations was TWD 0.61 compared to basic earnings per share from continuing operations of TWD 0.24 a year ago. Diluted loss per share from continuing operations was TWD 0.61 compared to diluted earnings per share from continuing operations of TWD 0.24 a year ago.